A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis
BP42230
Phase 1 other active
Quick answer
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis for Multiple Sclerosis (MS) is a Phase 1 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Multiple Sclerosis (MS)
- Phase
- Phase 1
- Modality
- other
- Status
- active